Table 2.
Univariate and multivariate analyses of progression-free survival.
| N | Univariate | P | Multivariate | P | |
|---|---|---|---|---|---|
| Age, years | |||||
| <70 | 16 | 1 (ref) | 1 (ref) | ||
| ≥70 | 19 | 0.617 [0.302-1.263] | .187 | 0.522 [0.226-1.205] | .128 |
| Sex | |||||
| Female | 10 | 1 (ref) | 1 (ref) | ||
| Male | 25 | 1.901 [0.841-4.296] | .123 | 1.830 [0.798-4.196] | .153 |
| ECOG performance status | |||||
| 0 | 22 | 1 (ref) | 1 (ref) | ||
| 1 | 13 | 2.113 [0.990-4.507] | .053 | 2.238 [0.941-5.322] | .068 |
| HER2 | |||||
| Negative + not tested | 26 | 1 (ref) | 1 (ref) | ||
| Positive | 9 | 2.139 [0.955-4.787] | .065 | 1.981 [0.829-4.736] | .124 |
| Liver metastasis | |||||
| Absent | 23 | 1 (ref) | 1 (ref) | ||
| Present | 12 | 1.431 [0.676-3.027] | .349 | 1.209 [0.461-3.170] | .699 |
| Peritoneum metastasis | |||||
| Absent | 17 | 1 (ref) | |||
| Present | 18 | 1.181 [0.590-2.365] | .639 | ||
| Measurable lesion | |||||
| Absent | 8 | 1 (ref) | |||
| Present | 27 | 0.968 [0.414-2.265] | .940 | ||
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2.